Drugs Made In America Acquisition II Corp (DMII) FinancialsDMIIDrugs Made In America Acquisition II Corp

Evaluating the bottom line, Drugs Made In America Acquisition II Corp. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 5.25%, provide a clear picture of how effectively DMII converts its operational activities into shareholder value.

In the context of the broader market, DMII competes directly with industry leaders such as BCSF and OIO. With a market capitalization of $648.15M, it holds a significant position in the sector. When comparing efficiency, DMII's gross margin of N/A stands against BCSF's 98.72% and OIO's 26.46%. Such benchmarking helps identify whether Drugs Made In America Acquisition II Corp. is trading at a premium or discount relative to its financial performance.

In the latest quarter (2026/Q2), DMII reported a net income of $4,396,456, with an EPS of $0.07, showing a positive trend compared to previous quarters. However, the current ratio is low at 0.34, indicating potential liquidity issues.